UK TO DELIST 62 MORE MEDICINES FROM NHS
The UK government has this month revealed the medicines and other products which it proposes to remove from eligibility for prescribing by general practitioners under the national Health Service. The list consists of 62 medicines, six nicotine replacement patch products and 583 "borderline substances" including herbal remedies, toiletries, sun protection creams and baby foods.
Health Minister Brian Mawhinney said that the proposals were being announced one month before regulations to bring them into force are due to go before parliament (Marketletter August 9), "so that all those with an interest have an opportunity to comment on them, and to provide any further information which they believe should be taken into account." The changes would not disadvantage patients, who will "continue to receive all the medicines they need," he said.
The 62 medicines to be delisted include the following 40 topical antirheumatics, the first of the ten additional delisting categories announced by Health Secretary Virginia Bottomley last November:
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze